

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)).

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW,

Washington, DC 20551-0001, not later than November 13, 2023.

A. Federal Reserve Bank of Dallas (Karen Smith, Director, Mergers & Acquisitions) 2200 North Pearl Street, Dallas, Texas 75201-2272. Comments can also be sent electronically to Comments.applications@dal.frb.org;

1. *Unifi Financial, Inc., San Antonio, Texas*; to become a bank holding company by acquiring Stockmens National Bank in Cotulla, Cotulla, Texas.

Board of Governors of the Federal Reserve System.

Michele Taylor Fennell,

Deputy Associate Secretary of the Board.

[FR Doc. 2023-22490 Filed 10-10-23; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2013-N-0804; FDA-2010-N-0598; FDA-2022-N-0081; FDA-2022-N-1886; FDA-2022-N-2657; FDA-2023-N-0895; FDA-2023-N-0343; FDA-2023-N-0134; FDA-2022-N-3208; FDA-2017-N-0084; FDA-2023-N-1168; FDA-2016-N-2474; FDA-2014-N-0086; FDA-2017-N-0366; FDA-2019-N-3657; FDA-2023-N-0155; FDA-2010-N-0601; FDA-2023-N-2757]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: JonnaLynn Capezzuto, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-3794, PRASStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: The following is a list of FDA information collections recently approved by OMB under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The OMB control number and expiration date of OMB approval for each information collection are shown in table 1. Copies of the supporting statements for the information collections are available on the internet at <https://www.reginfo.gov/public/do/PRAMain>. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

TABLE 1—LIST OF INFORMATION COLLECTIONS APPROVED BY OMB

Title of collection	OMB control No.	Date approval expires
Premarket Notification Submission 510(k), Subpart E	0910-0120	7/31/2026
Good Manufacturing Practice Regulations for Type A Medicated Articles	0910-0154	7/31/2026
Tradeoff Analysis of Prescription Drug Product Claims in Direct-to-Consumer and Healthcare Provider Promotion	0910-0917	7/31/2026
Endorser Status and Actual Use in Direct-to-Consumer Television Ads	0910-0918	7/31/2026
Assessing Physiological, Neural and Self-Reported Response to Tobacco Education Messages	0910-0919	7/31/2026
Imports and Electronic Import Entries	0910-0046	8/31/2026
Current Good Manufacturing Practices for Blood and Related Regulations for and Blood Components; and Requirements for Donor Testing, Donor Notification, and "Lookback"	0910-0116	8/31/2026
Administrative Practices and Procedures; Formal Hearings	0910-0191	8/31/2026
Adverse Experience/Events with Approved New Animal Drugs	0910-0284	8/31/2026
Adverse Event Program for Medical Devices (Medical Product Safety Network (MedSun))	0910-0471	8/31/2026
Human Cells, Tissues, and Cellular and Tissue-Based Products	0910-0543	8/31/2026
New Animal Drugs for Minor Use and Minor Species	0910-0605	8/31/2026
Potential Tobacco Product Violations Reporting Form	0910-0716	8/31/2026
Food and Drug Administration Advisory Committee Regulations	0910-0833	8/31/2026
Accreditation Scheme for Conformity Assessment Program	0910-0889	8/31/2026
Quantitative Research on Front of Package Labeling on Packaged Foods	0910-0920	8/31/2026
Current Good Manufacturing Practice Regulations for Medicated Feed	0910-0152	9/30/2026
Medical Devices—Voluntary Improvement Program	0910-0922	9/30/2026